Showing results (81-90 of 291) with videos related to

Sort By:
Pageof 30
Cardiovascular Research|May 1, 1995
Selective ETA receptor antagonism with BQ-123 is insufficient to inhibit angioplasty induced neointima formation in the ratS A Douglas, L M Vickery-Clark, C Louden, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 1, 1987
Enhanced pulmonary alpha-2 adrenoceptor responsiveness under conditions of elevated pulmonary vascular toneR J Shebuski, E H Ohlstein, J M Smith, et al.
Journal of Cardiovascular Pharmacology|January 1, 1995
Pharmacologic evidence for the presence of three functional endothelin receptor subtypes in rabbit saphenous veinS A Douglas, G R Beck, J D Elliott, et al.
The Annals of Thoracic Surgery|August 23, 2001
Effect of endothelin receptor antagonist on lung allograft apoptosis and NOSII expressionM J Shaw, H Shennib, N Bousette, et al.
Journal of Cardiovascular Pharmacology|January 1, 1995
Agonist-dependent inhibition by peptide and nonpeptide endothelin receptor antagonists in the rabbit isolated pulmonary arteryG R Beck, S A Douglas, J D Elliott, et al.
Journal of Applied Physiology (Bethesda, Md. : 1985)|January 1, 1991
Analysis of responses to endothelins in the rabbit pulmonary and systemic vascular bedsH L Lippton, E H Ohlstein, W R Summer, et al.
Life Sciences|January 1, 1994
Human laminin produces human platelet aggregation in vitroR N Willette, B L Storer, R K Clark, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 1, 1994
Angiotensin type 1 receptors mediate smooth muscle proliferation and endothelin biosynthesis in rat vascular smooth muscleC P Sung, A J Arleth, B L Storer, et al.
Pharmacology|December 17, 1997
Inhibition of sympathetic outflow by the angiotensin II receptor antagonist, eprosartan, but not by losartan, valsartan or irbesartan: relationship to differences in prejunctional angiotensin II receptor blockadeE H Ohlstein, D P Brooks, G Z Feuerstein, et al.
Medicinal Research Reviews|July 1, 1996
Endothelin receptors: receptor classification, novel receptor antagonists, and potential therapeutic targetsE H Ohlstein, J D Elliott, G Z Feuerstein, et al.
Pageof 30